Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Oxycodone That Can't Be Abused or Misused

By HospiMedica staff writers
Posted on 22 Sep 2004
A new long-acting version of oral oxycodone incorporates features that prevent recreational use, prescription abuse, or accidental misuse.

Called Remoxy, the pain medication is now in clinical trials designed to confirm anti-abuse studies and pharmacokinetic studies. More...
Abusers can easily extract the full dose of oxycodone from currently marketed time-release preparations, which provides abusers with a fast and powerful morphine-like high. In 2002, oxycodone abuse resulted in more than 20,000 visits to emergency rooms and hundreds of deaths.

The new drug was developed by Pain Therpeutics, Inc. (South San Francisco, CA, USA). Remoxy incorporates deterrent properties and offers the convenience of twice-a-day dosing. Tests indicate that crushing or physically manipulating Remoxy does not defeat its time-release mechanism. The drug can also resist extraction by acids or alcohol for hours at a time by entrapping a majority of the oxycodone inside its proprietary formulation. Under a license agreement, Remoxy is formulated with the Saber technology of Durect Corp. (Cupertino, CA, USA). Saber is a patented technology based on sucrose acetate isobutyrate, a high-viscosity biodegradable liquid matrix that forms the basis for a number of different drugs.

"As oxycodone abuse has no national barriers, we continue to envision Remoxy as a safe, effective and reliable alternative to time-release oxycodone both in the U.S. and abroad,” noted Remi Barbier, president and CEO of Pain Therapeutics.




Related Links:
Pain Therapeutics

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.